Core Insights - Elutia Inc. reported a 16% year-over-year increase in fourth quarter revenue, reaching approximately $3.3 million, and eliminated $26.9 million of secured debt, ending the year with total cash and escrowed proceeds of $44.3 million [1][8]. Company Developments - The company is advancing its NXT-41x antibiotic-eluting biomatrix program, which is expected to improve outcomes in breast reconstruction, a market valued at $1.5 billion with a post-operative infection rate of 15-25% [2][5]. - Elutia plans to submit an FDA filing for NXT-41 in the first half of 2026, with anticipated FDA clearance in the second half of 2026, followed by FDA clearance for NXT-41x in the first half of 2027 [3]. Financial Position - As of December 31, 2025, Elutia had approximately $36.3 million in cash, with an additional $8.0 million from the BioEnvelope divestiture held in escrow, expected to be released in 2026 [8]. - The company has a strong balance sheet, having repaid its outstanding debt, which will significantly reduce interest expenses moving forward [8].
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones